Learning Center Home
Educational Content
Search
Contact Us
IBMS Home
BoneKEy
IBMS 2nd Joint Meeting of the International Bone & Mineral Society
Session List
Click
here
to search this conference.
Display sessions grouped by:
Track
Session Code
Speaker
Date
Track
:
Free Communication
Opening Ceremony
Symposium
Workshop
Free Communication
030 Free Communication 1
030-1 Contributions of the FTO gene to fracture risk
030-2 A variant of human aromatase predicts increased circulating estradiol and bone health in post-menopausal women.
030-3 Sexual Dimorphism in the Asssembly of Metaphysela Cortical and Trabecular Architecture
030-4 Racial Differences in Macro and Micrarchitecture of the Appendicular Skeleton in Young Chinese and Caucasion Females
030-5 Glucocorticoid-induced cortical bone loss is mediated by osteoblast-controlled activation of bone resorption
030-6 Role of Bone Density and Clinical Risk Facctors in Mortality Risk Following All Osteporotic Fractures in Elderly Women and Men: An 18-year Prespective Study from Dubbo Osteoporosis Epidemiology Study
030-7 In vivo quantification of age-related changes in human cortical bone thickness and porosity by HR-pQCT
030-8 Pressentation of Copp Award to Stephen Krane
070 Free Communication 2a
070-1 Proteolytically processed repressor Gli3 inhibits bone formation by repressing BMP2 transcription in osteoblasts
070-2 Cthrc1 is a positive regulator of osteoblastic bone formation
070-3 Protein phosphatase magnesium-dependent 1A inhibits BMP signaling by stimulating Smad degradation independent of dephosphorylation at the carboxl termini
070-4 AP-1 function in mesenchymal cell fate decision:The role of Ribosomal S6 Kinase and Fra1
070-5 CREB induces BMP2 transcription in osteoblasts and CREB knockout reduces bone mass in mice
080 Free Communication 2b
080-1 Osteoblast IL-33 mRNA expression is regulated by PTH and IL-33 treatment causes both increased osteoblastic matrix mineralisation and reduced osteoclast formation invitro
080-2 A dairy-based protein, calcium and Vitamin D supplement preserves trabecular bone and reduces falls in aged care residents
080-3 Mechanical stress enhances osteoblast differentiation via canonical Wnt pathway
080-4 Osteoblast specific Y1deletion enhance3s bone formation
080-5 CNTF regulates mineralisation and plays critical sex-specific roles in bone formation
120 Free Communication 3
120-1 A Novel Small Thienoindazole-Derivative Compound Induces Chondrogenic Differentiation without Promoting Hypertrophy through Production of Runx1
120-2 Osteomac are critical for optimal itramembranous bone formation in a tibial defect model of bone healing
120-3 Regulation of adipogenesis by Zfp467, a novel zinc-finger protein
120-4 Calcitonin attenuates the anabolic effect of PTH in young rats by rapid upregulation of sclerostin expression
120-5 Ephrin B2 - EphB4 effects in osteoblast differentiation: role of RHOA signaling
120-6 Role of neuropeptide Y in control of bone formation in leptin deficient mice
120-7 Murine Oncostatin M (mOSM) regulates osetoblastic genes through a novel receptor
120-8 OsteoMacs maintain the endosteal hematopoetic stem cell niche and participate in mobilization
120-9 Presentation of Fleisch Award to Michael Rogers
160 Free Communication 4a
160-1 A fusion protein of parathyroid hormone (PTH) and a collagen binding domain shows superior efficacy and longer duration of action compared to PTH(1-34) as an anabolic bone agent in normal female mice
160-2 Skeletal Anabolic Activity of Cannabinoid Receptor Agonists
160-3 Effects of denosumab and alendronate on skeletal microarchitecture
160-4 A Double-Blind, Placebo-Controlled, Phase III Study of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women: Effects on Bone Mineral Density
160-5 Efficacy of risedronate against hip fracture in patients with neurological diseases: A metaanalysis of randomized controlled trials
170 Free Communications 4b
170-1 Impact of alfacalcidol on bone mineral density (pQCT&DXA) of radius, tibia, spine and hip in postmenopausal alendronate treated women with reduced bone mass
170-2 Effective osteoporosis treatments reduce mortality: a meta-analysis
170-3 Lifestyle impact on lifetime bone loss in women and men. The Tromsø Study
170-4 Do men and women have similar absolute risk of fracture?
170-5 Fracture risk and access to funded osteoporosis treatments in New Zealand, Australia, UK and Canada
210 Free Communication 5
210-1 Hypoxia-inducible factor 2 (HIF-2 ) controls sequential steps of endochondral ossification during skeletal growth and osteoarthritis progression
210-2 Identification of a Transcription Factor p63 for Joint Cartilage Formation by Analyses of Wnt9a and Gdf5 Promoters
210-3 Loss of a single bim allele recovers the defective osteoclast function in bcl-2-/- mice but does not restore the anabolic action of PTH
210-4 Micro RNA 18a regulates chondrocytic phenotype: Involvement of Ccn2/Ctgf as a major target gene
210-5 A transcription factor Znf219 regulates chondrogenesis by forming a transcription factory complex with Sox9
210-6 C/EBP / p57Kip2 Signaling Maintains Transition from Proliferation to Hypertrophic Differentiation of Chondrocytes during Skeletal Growth
210-7 Androgen/androgen receptor directly acts in trabecular osteoclasts and cortical osteoblasts
210-8 Nkx3.2 is an important mediator of hypoxia-induced chondrocytic differentiation
250 Free Communication 6a
250-1 CCN2/CTGF has anti-aging effects to protect articular cartilage from age-related degenerative changes
250-2 Inhibitory Role of G q / PKC Signal in the Bone Anabolic Action of PTH
250-3 Monocytes Control Mesenchymal Stem Cell Differentation Towards Osteoblasts
250-4 Strontium ranelate amplifies the effects of PTH by improving the intrinsic tissue quality of the newly formed bone
250-5 Vertebral fracture risk and alendronate effects in postmenopausal women assessed by CTbased nonlinear finite element analysis
260 Free Communications 6b
260-1 Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation and a novel non-UBA domain mutation (P364S) associated with increased NF- B signalling without loss of ubiquitin-binding
260-2 Class IA phosphatidylinositol 3-kinases are indispensable for osteoclast function by regulating cytoskeletal organization and cell death
260-3 DC-STAMP regulates bone homeostasis through cell-cell fusion of osteoclasts
260-4 Ror2 signaling enhances osteoclast formation in physiological and pathological conditions
260-5 Essential role of small GTPase Rac1 during limb development
290 Free Communication 7a
290-1 A randomized trial of balloon kyphoplasty and nonsurgical care for acute vertebral compression fracture
290-2 Enzyme replacement therapy (ERT) for murine hypophosphatasia
290-3 Association between Hyperglycemia and Fracture Risk in Non-diabetic Middle-aged and Older Australians: A National, Population based Prospective Study (AusDiab)
290-4 Effects of Risedronate on Bone Marrow Adipocytes in Postmenopausal Women
290-5 Skeletal dysplasia and lethality in mice lacking the mid-region, nuclear localization signal and cterminus of parathyroid hormone-related protein
300 Free Communications 7b
300-1 Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease
300-2 Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression
300-3 STAT3 induces osteoblastic bone metastases through up-regulating the expression of leptin and leptin receptors in the LNCaP human prostate cancer
300-4 Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma
300-5 Osteosarcoma metastasis: Evidence for ACP5 downregulation and osteoclast involvement
310 Closing Ceremony & Awards
Back to Top
Opening Ceremony
010 Opening Ceremony
010-1 Indigenous welcome to the country
010-2 Opening Plenary: Advances in understanding the molecular basis of bone remodelling: past, present and future
010-3 Presentation of Rodan Fellowship to Fabienne Coury-Lucas
010-4 Presentation of Gaillard Award to Gregory Mundy
Back to Top
Symposium
020 Scientific Symposium 1 - Genetics
020-1 Genetic Determinants of Locomotor Disease
020-2 Genetic models of bone disease using ENU mutagenesis
060 Symposium 2 - Mechanosensing
060-1 Estrogen Receptor is a Critical Contributor at Multiple sites to Bones'' Adaptive Response to Mechanical Loading
060-2 Winning the battle against childhood physical inactivity: the key to bone strength?
090 Servier Symposium - Influencing bone remodelling and fracture risk
090-1 Strontium Ranelate mode of action and effects on bone remodeling
090-2 Do all agents have equal evidence?
100 Sanofi-Aventis/ Procter & Gamble Symposium - Emerging data for osteoporosis management
100-1 Broadening our knowledge through GLOW (Global Longitudinal study of Osteoporosis in Women)
100-2 Differences between bisphosphonates: from mechanism of action to real life studies
110 Scientific Symposium 3 - Bone & Cardiovascular Disease
110-1 Skeletal stem cells and the microvascular system of tissue specific progenitors
110-2 Arteriosclerosis and Bone Disease
150 Symposium 4 — What's New in Osteoporosis
150-1 Contribution of genetic factors to the individualized prognosis of fracture
150-2 Future Management of Osteoporosis
180 Amgen Symposium - RANK Ligand Inhibition from Bench to Bedside
180-1 Cortical Bone: Neglecting Samson's Hair and Achilles' Heel
180-2 RANK Ligand inhibition: Experiences from rodents to primates
180-3 RANK Ligand inhibition in patients with postmenopausal bone loss
190 Merck Symposium Osteoporosis: Highlighting the Progress of Novel Therapeutic Strategies
190-1 Vitamin D in Health and Disease
190-2 Treatment of Osteoporosis: New developments
190-3 Chairman's Closing Remarks
200 Scientific Symposium 5 - Osteoblasts
200-1 Wnt and Hh signaling in skeletal development and homeostasis
200-2 Neurogenic Regulation of Osteoblast Function
240 Symposium 6 — Rare bone diseases
240-1 Management of Osteogenesis Imperfecta
240-2 Debate on Management of Paget''s Disease - "The Aim of Treatment is to Restore Normal Bone Turnover"
270 Eli Lilly Symposium Postmenopausal health: new care strategies for women with multiple risks
270-1 Role of bone quality in the pathogenesis of fragility fractures
270-2 Teriparatide: the optimal choice for treatment of primary and secondary severe osteoporosis
270-3 SERMs: chemoprevention of fragility fractures and invasive breast cancer
280 Scientific Symposium 7 - Cancer & Bone
280-1 Pathophysiology of Bone Metastasis
280-2 Management of Cancer and Bone — Trials and Tribulations
Back to Top
Workshop
040 Workshop 1 - Fracture Repair
040-1 Biology of Fracture Healing and Effect of Osteoporosis Therapies
040-2 Bone Morphogenetic Proteins (BMPs) and fracture repair
040-3 Stem Cells and Fracture Repair
050 Workshop 2 - Osteoclasts
050-1 Nucleotides and regulation of bone cell function
050-2 Cytokines that signal through gp130 and their roles in bone biology
050-3 Sex Steroid Hormones Exhibit Osteoprotecitve Effects Through Nuclear Receptors Expressing In Bone Cells
130 Workshop 3 - Fundamentals of Bone Quality
130-1 On the Origins of Fracture Resistance and its Biological Degradation in Human Bone
130-2 Nanoscale Deformation Mechanisms in Bone
130-3 TGF-beta and Bone Matrix Material Properties
140 Workshop 4 - Falls and Fractures
140-1 Strategies for preventing falls in the elderly
140-2 Bone Microarchitecture and Fracture Risk
140-3 Vitamin D, Falls and Fractures What''s New?
220 Workshop 5 - Osteocytes
220-1 Functional morphology of osteocytes
220-2 Molecular biology of osteocytes
220-3 Osteocyte controls Pi homeostasis
230 Workshop 6 - Vertebral Fractures
230-1 Epidemiology of Vertebral Fractures
230-2 New apoproaches to diagnosis of vertebral fractures
230-3 Vertebroplasty and Kyphoplasty
Back to Top